Ruthenium imidazole oxime carbonyls and their activities as CO-releasing molecules.
Summary of "Ruthenium imidazole oxime carbonyls and their activities as CO-releasing molecules."
Carbon monoxide has been found to possess various beneficial effects in living organisms. To study the effects of CO further and to develop potential pharmaceutical agents, a meaningful method for delivering CO to the target organ is needed. It has been found that under physiological conditions various metal carbonyl complexes release carbon monoxide. In this study six novel ruthenium carbonyl complexes Ru(IMOX)(CO)(2)(COOR)Cl(1) (
IMOX:
imidazolecarbaldehyde oxime,
R:
Me, Et) were prepared and tested as carbon monoxide releasing molecules (CORMs). Synthesis of the complexes was performed under mild conditions in alcoholic solutions. The ability to release CO was tested spectrophotometrically by following the transformation of deoxymyoglobin to carbonmonoxy myoglobin. All of the complexes studied were found to release CO. Compared to formerly studied ruthenium-based CORMs these complexes offer a way for slower CO release.
Affiliation
Department of Chemistry, University of Eastern Finland, Joensuu Campus, P.O. Box 111, FI-80101 Joensuu, Finland. larisa.oresmaa@uef.fi.
Journal Details
This article was published in the following journal.
Name: Dalton transactions (Cambridge, England : 2003)
ISSN: 1477-9234
Pages:
Links
- PubMed Source: http://www.ncbi.nlm.nih.gov/pubmed/22868452
- DOI: http://dx.doi.org/10.1039/c2dt31002c
Medical and Biotech [MESH] Definitions
Ruthenium Radioisotopes
Unstable isotopes of ruthenium that decay or disintegrate emitting radiation. Ru atoms with atomic weights 93-95, 97, 103, and 105-108 are radioactive ruthenium isotopes.
Ruthenium Compounds
Inorganic compounds that contain ruthenium as an integral part of the molecule.
Ruthenium Red
An inorganic dye used in microscopy for differential staining and as a diagnostic reagent. In research this compound is used to study changes in cytoplasmic concentrations of calcium. Ruthenium red inhibits calcium transport through membrane channels.
Gtp Cyclohydrolase
(GTP cyclohydrolase I) or GTP 7,8-8,9-dihydrolase (pyrophosphate-forming) (GTP cyclohydrolase II). An enzyme group that hydrolyzes the imidazole ring of GTP, releasing carbon-8 as formate. Two C-N bonds are hydrolyzed and the pentase unit is isomerized. This is the first step in the synthesis of folic acid from GTP. EC 3.5.4.16 (GTP cyclohydrolase I) and EC 3.5.4.25 (GTP cyclohydrolase II).
Receptors, Corticotropin-releasing Hormone
Cell surface proteins that bind corticotropin-releasing hormone with high affinity and trigger intracellular changes which influence the behavior of cells. The corticotropin releasing-hormone receptors on anterior pituitary cells mediate the stimulation of corticotropin release by hypothalamic corticotropin releasing factor. The physiological consequence of activating corticotropin-releasing hormone receptors on central neurons is not well understood.
PubMed Articles
The physiological roles of CO in neurotransmission, vasorelaxation, and cytoprotective activities have raised interest in the design and syntheses of CO-releasing materials (CORMs) that could be emplo...
Iron indenyl carbonyl compounds: CO-releasing molecules.
New CO-releasing molecules, CO-RMs, based on indenyl iron carbonyls have been identified. Half-lives for carbon monoxide (CO) release, (1)H NMR, (13)C NMR, IR, mass spectra, elemental analysis and bio...
Using the combinations of imidazole and dimethyl sulfoxide (DMSO) as axial ligands and 2,2'-bipyridine-6,6'-dicarboxylate (bda) as the equatorial ligand, we have synthesized six novel ruthenium comple...
Nitric oxide-releasing ruthenium nanoparticles.
Nitric oxide-releasing ruthenium nanoparticles were synthesized by the reaction of alkanethiolate-protected ruthenium nanoparticles with tert-butyl nitrite ((t)BuONO), and their water-soluble derivati...
CH activation by acetate-assisted cyclometallation of a phenyl group with half-sandwich complexes [{MCl(2) Cp*}(2) ] (M=Ir, Rh) and [{RuCl(2) (p-cymene)}(2) ] can be directed by a wide range of nit...
Clinical Trials
This is a phase 2, randomized, active-controlled, parallel-group, multicenter, single-blind trial of three different doses of etonogestrel releasing medicated intrauterine systems (ENG-MIU...
OBJECTIVES: I. Determine whether release of endogenous growth hormone (GH)-releasing hormone is involved in GH responses to clonidine, pyridostigmine, levodopa, arginine, GH-releasing pep...
RATIONALE: Androgens can cause the growth of prostate cancer cells. Luteinizing hormone-releasing hormone agonists may lessen the amount of androgens made by the body. Internal radiation u...
Safety of the Etonogestrel-Releasing Implant During the Puerperium of Healthy Women
The purpose of this study to assess the safety of the etonogestrel-releasing subdermal implant (Implanon) inserted during the immediate puerperium of healthy women.
The study is a randomized controlled trial comparing outcomes of immediate postplacental insertion of the levonorgestrel-releasing intrauterine system (LNG-IUS) vs. interval insertion of t...
